Incident hepatocellular carcinoma in patients with type 2 diabetes, with and without MASLD/MASH/liver fibrosis and cirrhosis (Comparison between propensity-score matched cohorts)

Cohort size	Exposure cohort	Comparison cohort	# of cases (overall risk) (Exposure cohort)	# of cases (overall risk) (Comparison cohort)		HR (95% CI)
no M	ASLD/MASH/Liver fibrosis and cirrl	hosis				
 42,703	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	16 (0.04%)	86 (0.20%)		0.18 (0.11–0.31)
42,809	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	68 (0.16%)	78 (0.18%)	⊢ ■	0.90 (0.65-1.24)
95,667	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	135 (0.14%)	144 (0.15%)	⊢ ■ 1	0.86 (0.68-1.09)
49,132	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	68 (0.14%)	88 (0.18%)	⊢ •	0.73 (0.53-1.01)
86,301	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	117 (0.14%)	136 (0.16%)	├─■	0.81 (0.63-1.04)
59,082	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	100 (0.17%)	94 (0.16%)	⊢	1.01 (0.76–1.33)
	MASLD/MASH					
3,505	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	<10 (<0.29%)	28 (0.80%)		0.34 (0.17–0.70)
2,825	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	37 (1.31%)	31 (1.10%)	⊢	1.21 (0.75–1.95)
6,167	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	63 (1.02%)	52 (0.84%)	- ■ - 	1.11 (0.77–1.60)
3,388	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	42 (1.24%)	41 (1.21%)	├──┿	0.98 (0.64–1.51)
6,182	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	64 (1.04%)	58 (0.94%)	├	1.03 (0.72–1.47)
2,908	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	32 (1.10%)	30 (1.03%)	⊢	0.99 (0.60-1.62)
	liver fibrosis and cirrhosis					
492	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	<10 (<2.03%)	25 (5.08%)		0.27 (0.12–0.63)
1,035	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	62 (5.99%)	55 (5.31%)	⊢	1.14 (0.79–1.64)
1,641	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	97 (5.91%)	80 (4.88%)	⊢	1.12 (0.84–1.51)
958	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	59 (6.16%)	57 (5.95%)	├	1.03 (0.72–1.49)
1,597	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	88 (5.51%)	94 (5.89%)	⊢ ■	0.86 (0.64–1.15)
865	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	54 (6.24%)	35 (4.05%)	0.20 0.30 0.500.70 1.0 2.0 3.004.0	1.48 (0.97–2.26)